Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

Amgen467 enrolled

Overview

The study is divided into 2 parts. The first part of the study will be double-blinded and will last for 24 weeks. During this time, participants will be randomized in a ratio of 2:1 to receive either evolocumab once monthly (QM) or placebo QM. The second part of the study is a 24-week open label extension period. During this time all participants will receive evolocumab QM. The clinical hypothesis is that subcutaneous evolocumab QM will be well tolerated and will result in greater reduction of low density lipoprotein cholesterol (LDL-C), defined as percent change from baseline at Week 24, compared with placebo QM in human immunodeficiency virus (HIV)-positive participants with hyperlipidemia or mixed dyslipidemia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

467

Conditions

Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female ≥ 18 years of age * Known HIV infection with stable HIV therapy for ≥ 6 months * Cluster of differentiation 4 (CD4) ≥ 250 cells/mm\^3 for ≥ 6 months * HIV viral load ≤ 50 copies/mL at screening and ≤ 200 copies/mL for ≥ 6 months * Subject on stable lipid-lowering therapy for ≥ 4 weeks prior to randomization and not expected to change during the duration of study * For subjects with known clinical atherosclerotic cardiovascular disease (ASCVD), fasting LDL-C of ≥ 70 mg/dL or non-high density lipoprotein cholesterol (non-HDL-C) ≥ 100 mg/dL. For subjects without known clinical ASCVD: fasting LDL-C of ≥ 100 mg/dL or non-HDL-C of ≥ 130 mg/dL * Fasting triglycerides ≤ 600 mg/dL (6.8 mmol/L) Exclusion Criteria: * Taking a combination of background lipid-lowering therapy and HIV therapy known to have significant drug-drug interaction * New York Heart Association (NYHA) III or IV heart failure, or last known left ventricular ejection fraction (LVEF) \< 30% * Known opportunistic infection/acquired immunodeficiency syndrome (AIDS) defining illness within 1 year prior to randomization * Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft or stroke within 3 months * Type 1 diabetes, new-onset or poorly controlled type 2 diabetes * Uncontrolled hypertension * Taken a cholesteryl ester transfer protein inhibitor in the last 12 months * Moderate to severe renal dysfunction * Persistent active liver disease or hepatic dysfunction (Stable chronic hepatitis C of at least 1 year duration prior to randomization is allowed) * Malignancy (except non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in-situ, or stage 1 prostate carcinoma) within the last 5 years prior to randomization Other exclusion criteria may apply.

Locations (78)

Research Site

Los Angeles, California, United States

Research Site

Hartford, Connecticut, United States

Research Site

Washington D.C., District of Columbia, United States

Research Site

Washington D.C., District of Columbia, United States

Research Site

Washington D.C., District of Columbia, United States

Outcomes

Primary Outcomes

Percent Change From Baseline in LDL-C at Week 24

Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)

Time frame: Baseline, Week 24

Secondary Outcomes

Change From Baseline in LDL-C at Week 24

Time frame: Baseline, Week 24

Percentage of Participants Acheiving LDL-C < 70 mg/dL (1.8 mmol/L) at Week 24

Time frame: Week 24

Percentage of Participants With an LDL-C Response (50% Reduction of LDL-C From Baseline) at Week 24

Time frame: Baseline, Week 24

Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (HDL-C) at Week 24

Time frame: Baseline, Week 24

Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24

Time frame: Baseline, Week 24

Percent Change From Baseline in Total Cholesterol (TC) at Week 24

Time frame: Baseline, Week 24

Percent Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 24

Time frame: Baseline, Week 24

Percent Change From Baseline in Triglycerides at Week 24

Time frame: Baseline, Week 24

Percent Change From Baseline in HDL-C at Week 24

Time frame: Bseline, Week 24

Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C) at Week 24

Time frame: Baseline, Week 24